Ysios's investment strategy allows for investments in early stage companies looking for first round funding through to later-stage or pharmaceutical spin-off companies. Our investments target companies focusing on product development in the biotechnology, emerging pharmaceuticals, healthcare and medical technology sectors.

Ysios Capital Partners has a clearly defined investment strategy whereby we focus on investing in human healthcare innovation projects primarily in Spain, although we may invest up to 30% of the fund size outside Spain. We aim to balance risk and liquidity against the stage of investment-from seed capital to pre-IPO-investing in various subsectors with different time-to-market horizons, capital needs and risk-to-return ratios.

Ysios Capital Partners can make investments ranging from EUR 500'000 to EUR 4 million, reserving additional capital for follow-on investments. When we decide to invest in a company in Spain, we will typically play the lead or co-lead investor role in structuring the transaction, always syndicating with other venture capital firms. In major financing operations, especially in those circumstances where we can leverage on our national networks, we seek to invest in international syndicates with other dedicated Life Sciences and Healthcare investors that share with Ysios Capital Partners our vision and commitment to investing in and supporting companies.